AMN Healthcare Announces Upsize and Pricing of Senior Notes Offering

On August 10, 2020 AMN Healthcare Services, Inc. (NYSE: AMN), reported that its wholly owned subsidiary, AMN Healthcare, Inc. (the "Issuer"), priced its private offering of an additional $200 million aggregate principal amount of 4.625% Senior Notes due 2027, which represents an increase of $50 million from the aggregate principal amount previously disclosed (the "New Notes") (Press release, AMN Healthcare Services, AUG 10, 2020, View Source [SID1234563368]). The New Notes will be issued at 101.00% of their face value. The New Notes will be issued under the existing indenture, dated as of October 1, 2019, under which the Issuer previously issued $300 million aggregate principal amount of its 4.625% Senior Notes due 2027. The New Notes will be guaranteed by the Company’s affiliates that guarantee the Company’s credit facilities ("Credit Facilities").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Issuer intends to use the proceeds from the private offering to (i) repay a portion of the existing term loan indebtedness under the Credit Facilities and (ii) pay fees and expenses related to the offering.

The offering is expected to close August 13, 2020, subject to satisfaction of customary closing conditions.

The New Notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933 (as amended, the "Securities Act") and to non-U.S. persons outside of the United States in compliance with Regulation S under the Securities Act. The New Notes will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.